Eli Lilly is walking through the Gate, inking a deal worth up to $856 million with a biotech aiming to build out a new ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

ABEC’s large-scale CSR Bioreactors will be at the heart of the facility, and ABEC will also manufacture, test, and install large-scale CSR GenMix systems. Equipment deliveries are scheduled for ...

Verve Therapeutics stock skyrocketed after pharmaceutical giant Eli Lilly said it was buying the gene-editing start-up for up to $1.3 billion. As part of the agreement, Lilly will acquire all ...

(Reuters) -Eli Lilly will acquire gene-editing startup Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday, accelerating a push into experimental cardiovascular therapies.